Shamik Parikh
Bristol-Myers Squibb / AstraZeneca, , United States
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
Response to dapagliflozin by baseline HbA1c in head-to-head comparisons (#369)
2:00 PM
Shamik J Parikh
ADS Clinical Poster Discussions
Combined HbA1c and weight reduction is achieved more frequently with add-on dapagliflozin than add-on glipizide in patients with type 2 diabetes inadequately controlled on metformin (#370)
2:00 PM
Shamik J Parikh
ADS Clinical Poster Discussions